

Luxembourg, October 2025

Public

Environmental and Social Data Sheet¹

Overview

Project Name:	XELTIS RDI (IEU TI 2)
Project Number:	2025-0260
Country:	Netherlands
Project Description:	Financing of R&D to further develop transformative vascular implants using supramolecular chemistry. The project focuses on solutions for vascular access, coronary and peripheral bypass grafts, and pulmonary heart valves.

EIA required:	no
Invest EU sustainability proofing required	yes
Project included in Carbon Footprint Exercise ² :	no

Environmental and Social Assessment

The project concerns investments in research and development activities, including product development and clinical trials, to develop vascular implants for various surgical applications.

Environmental Assessment

The project concerns investments in research and development activities carried out by the Company and its partners in existing facilities without changing their already authorised scope. The research and development activities of the project do not fall under either Annex I or Annex II of the EIA Directive 2011/92/EU amended by Directive 2014/52/EU, therefore an EIA is not required.

Climate Assessment

The project has been assessed for Paris alignment and is considered to be aligned with both low-carbon and resilience goals as per the policies set up in the Climate Bank Roadmap and/or associated guidance and other relevant documents (e.g. the Energy Lending Policy).

¹ The information contained in the document reflects the requirement related to the environmental, social and climate information to be provided to Investment Committee as required by the Invest EU Regulation and it represents the equivalent of the information required in the template of the InvestEU sustainability proofing summary

² Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO₂e/year absolute (gross) or 20,000 tonnes CO₂e/year relative (net) – both increases and savings.



Luxembourg, October 2025

EIB Paris Alignment for Counterparties (PATH) Framework

The Promoter is in scope but screened out of the PATH framework as it does not operate in a high-emitting sector and it is not considered as a highly-vulnerable counterpart.

Other Environmental and Social Aspects

Through the R&D activities and investments to develop vascular implants to treat haemodialysis patients and patients with cardiovascular diseases., the Company is expected to sustain its current level of highly skilled personnel while contributing to European scientific innovation, and vital research community.

The Company and its products are regulated to ensure quality and reliability of its medical products. Their quality management system is in compliance with the relevant quality management system regulations and the company is seeking compliance of their devices and panels with EU Regulation 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices (IVDR). The company also complies with the relevant EU regulations regarding animal testing and the protection of human subjects in research.

Conclusions and Recommendations

The project concerns investments in research and development and its activities do not fall under either Annex I or Annex II of the EIA Directive 2011/92/EU amended by Directive 2014/52/EU.

The Promoter has appropriate policies and operating procedures in place, which are in line with industry standards.

Sustainability proofing conclusion: The project is carried out in compliance with applicable national and EU environmental and social legislation. Based on the environment, climate and social (ECS) information, the review of the ECS risks and impacts and the management systems in place, the project is deemed to have non-significant ECS risks impacts. No further sustainability proofing is required.

Considering the above, taking into consideration the Environmental, Social and Climate impacts of this RDI project, including the capacity of the promoter and the overall net positive social impact, this project is deemed acceptable for the Bank's financing under environmental and social terms.